| Wang Jianfang,Sun Caiping,Liu Jianjiang,Ye Wanli,Chen Xialin.Randomized controlled trial of icotinib concurrent with thoracic radiotherapy for treating advanced non-small cell lung cancer (NSCLC)[J].Chinese Journal of Radiological Medicine and Protection,2017,37(4):269-272,281 |
| Randomized controlled trial of icotinib concurrent with thoracic radiotherapy for treating advanced non-small cell lung cancer (NSCLC) |
| Received:November 09, 2016 |
| DOI：10.3760/cma.j.issn.0254-5098.2017.04.006 |
| KeyWords:Non-small cell lung cancer EGFR Mutation Icotinib Thoracic radiotherapy |
| FundProject:浙江省卫生厅一般计划项目（2014KYB278） |
| Author Name | Affiliation | E-mail | | Wang Jianfang | Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, China | | | Sun Caiping | Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, China | | | Liu Jianjiang | Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, China | | | Ye Wanli | Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, China | | | Chen Xialin | Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, China | shitn8868@126.com |
|
| Hits: 3415 |
| Download times: 1927 |
| Abstract:: |
| Objective To compare the efficacy and safety of icotinib therapy alone versus icotinib combined with thoracic radiotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) patients with an activating epidermal growth factor receptor (EGFR) gene mutation.Methods A total of 83 patients with advanced NSCLC harboring an activating EGFR gene mutation was enrolled in this study. All the patients were randomly divided into 2 groups. Patients in group A (n=41) received thoracic radiotherapy (prescribed at 60-66 Gy) combined with icotinib (three times per day, 125 mg once). Patients in group B (n=42) were given icotinib therapy alone (three times per day, 125 mg once). Treatment was continued until disease progression or unacceptable toxicity or death. The primary end points were median progression-free survival (mPFS) and 12 month-PFS rate. The secondary end points included objective response rate (ORR), disease control rate (DCR) and adverse events. Results With a median follow-up of 18.2 months, mPFS was 15.2 months (95% CI: 12.2-17.4) in group A and 13.2 months (95% CI: 10.8-14.9) in group B (χ2=4.29, P=0.036). PFS rates of 12 months for group A and group B were 70.3% and 61.2%, respectively. The ORR were 78.0% vs. 57.1% (χ2=5.16, P=0.028), and the DCR were 95.1% vs. 92.9% (P>0.05) in groups A and group B, respectively. No grade 3-4 adverse events was observed in both groups except the rashes (4 cases in each group). Besides, 10 patients had grade 1-2 radiation-related pneumonitis and 15 patients suffered grade 1-2 radiation-related oesophagitis in group A.Conclusions In advanced NSCLC patients with an activating EGFR gene mutation, the combination of thoracic radiotherapy and icotinib had achieved an improvement on ORR and PFS with good tolerance. Clinical trial registration Chinese clinical trial registry, ChiCTR-INR-16010262. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
